Welcome to our dedicated page for INNOCAN PHARMA SEC filings (Ticker: INNPF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on INNOCAN PHARMA's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into INNOCAN PHARMA's regulatory disclosures and financial reporting.
Innocan Pharma Corporation is offering up to 3,750,000 Units (each Unit: one common share and one warrant) and up to 3,750,000 pre-funded Units in an initial public offering priced between $5.00 and $6.00 per Unit. The warrants have an exercise price of $6.875 and expire five years from issuance. The prospectus gives effect to a 65-for-1 reverse share split and states common shares to be outstanding after this offering of 8,248,772 (or 8,811,272 if the underwriter exercises the over-allotment in full). Based on a $5.50 midpoint, net proceeds to the company are expected to be approximately $17.98 million (about $20.82 million with full over-allotment). The offering includes an option to purchase up to 562,500 additional common shares and/or warrants to cover over-allotments. Use of proceeds highlights R&D for human and veterinary LPT-CBD programs, manufacturing scale-up, and U.S. marketing.